OS Therapies Incorporated (OSTX) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, OS Therapies Incorporated (NYSE: OSTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $1.24 (-4.61% 1D, market cap $67.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OSTX ranks #481 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OSTX carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ZYBT (Zhengye Biotechnology Holding Limited (Class A)) holds a D- grade (40/100 RQD, P/E N/A, ROIC -22.3%, cap $67.8M) and RNXT (RenovoRx Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $67.2M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while ZYBT leads on capital efficiency (-22.3% ROIC).
Per OSTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001795091), OS Therapies Incorporated generated $0 in revenue, -$28.8M in net income, and -$14.2M in free cash flow against $6.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 8% of 52W Range • RSI-14 at 33.8 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While OSTX currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.57) and Max Pain ($1.30) forces dealer call-delta covering toward $2.36.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
OS Therapies Incorporated (OSTX) dropped -4.61% to $1.24, trading at 8% of its 52-week range ($1.15 – $2.25). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Proceeds from the initial closing, together with accrued refundable U.K. R&D tax credits, expected to provide operating runway through major upcoming milestonesCompany expects to complete early market access regulatory a
Clinical-Stage Oncology Company Taps RPR to Drive Global Communications as Groundbreaking Cancer Immunotherapy Advances Toward ApprovalNEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Rubenstein Public Relations (RPR), a lead
Received notice for upcoming USDA meetingCompany is reviewing strategic alternatives to monetize OS Animal Health ("OSAH")Grasonville, Maryland--(Newsfile Corp. - October 7, 2026) - OS Therapies, Inc. (NYSE American: OST
Leading Clinical Stage Oncology Company Releases Significant Findings from OST-HER2-Treated Patients72.7 percent three-year overall survival vs. 45.8 percent comparable combined historical control (p = 0.0006)Company pre
Experienced biotech leaders to focus on preparations for U.S., U.K., and European commercial launch of the Company's lead product candidate Herlystic™(OST-HER2; daznelimgene lisbac)Grasonville, Maryland--(Newsfile Corp.
New York, New York and Rockville, Maryland--(Newsfile Corp. - September 24, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immun
Recent U.K. MHRA Scientific Advice Meeting (SAM) that resulted in full alignment to initiate confirmatory Phase 3 trial in U.K. with existing Phase 2 drug product paved the way Conditional Marketing Authorisation Applica
FDA aligns with MHRA and EMA on adaptive design for Phase 3 trialAfter successful Scientific Advice Meeting, OS Therapies accepts MHRA request to become the Company's sponsor into Project Orbis to harmonize regulatory re
Overall Survival (OS) historical-control data gains HMRA and EMA support for pending CMAA submissionsFull alignment achieved on confirmatory Phase 3 trial designComplete CMAA submission expected in coming weeksNew York,
71.2% 3-year overall survival for OST-HER2-treated patients vs. 45.8% comparable combined historical control (p = 0.002)The two remaining patients who have not yet reached the 3-year timepoint from enrollment have trial
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on OSTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for OSTX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, OS Therapies Incorporated (OSTX) ranks #481 by composite RQD confidence (42/100, grade D-) and #711 by equity capitalization ($67.6M). Within this direct 5-issuer industry benchmark cohort, MNOV leads on earnings valuation at 5.7x trailing P/E, while ZYBT leads on capital efficiency and profitability with -22.3% ROIC and 20.5% gross margin. OSTX currently leads its immediate peer cohort in composite quantitative strength at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OSTX
ACTIVE
OS Therapies Incorporated | D- | 42/100 | — | — | -35.0% | -4.61% | $67.6M | Benchmark Subject |
| ZYBT Zhengye Biotechnology Holding Limited (Class A) | D- | 40/100 | — | 20.5% | -22.3% | -9.09% | $67.8M | /zybt-vs-ostx → |
| RNXT RenovoRx Inc. | E | 31/100 | — | 70.9% | -35.0% | -10.74% | $67.2M | /rnxt-vs-ostx → |
| FBIO Fortress Biotech Inc. | D- | 39/100 | — | 66.9% | -35.0% | -4.00% | $66.7M | /fbio-vs-ostx → |
| MNOV Medicinova Inc | E | 30/100 | 5.7x | — | -35.0% | 0.00% | $68.9M | /mnov-vs-ostx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), OS Therapies Incorporated (OSTX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$28.8M, operating cash flow of -$14.2M, and free cash flow of -$14.2M (-95.5% YoY). On the balance sheet, OSTX closed FY2025 with $6.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$28.8M | -$14.2M | -$14.2M | $6.8M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$8.9M | -$7.3M | -$7.3M | $5.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$7.8M | -$3.0M | -$3.0M | — | — |
As of 2026-11-02, OS Therapies Incorporated (NYSE: OSTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $1.24 (-4.61% 1D, market cap $67.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OSTX ranks #481 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OSTX carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ZYBT (Zhengye Biotechnology Holding Limited (Class A)) holds a D- grade (40/100 RQD, P/E N/A, ROIC -22.3%, cap $67.8M) and RNXT (RenovoRx Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $67.2M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while ZYBT leads on capital efficiency (-22.3% ROIC).
Per OSTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001795091), OS Therapies Incorporated generated $0 in revenue, -$28.8M in net income, and -$14.2M in free cash flow against $6.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
OSTX last traded at $1.24 (-4.61% on volume of 321,734 shares), positioning the stock -21.02% below its 50-day simple moving average ($1.57) and -20.51% below its 200-day simple moving average ($1.56). Across its 52-week range of $1.15 to $2.25, OSTX sits at the 8.2% percentile with a 14-day RSI of 33.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.09 to $1.39).
Why OSTX Stock dropped -4.61% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD 5-pillar rating engine, OS Therapies Incorporated (OSTX) carries a composite score of 42/100 (D- — Roarable Sell — Vulnerable Balance Sheet & Flow) at a current price of $1.24 (-4.61%). Fundamental cash generation scores 7/20 (ROIC -35.0%, FCF yield -21.07%), institutional 13F whale accumulation scores 11/20, insider conviction scores 3/20, macro regime alignment scores 11/20 (Beta 1.00), and forensic balance-sheet protection scores 10/20 (Altman Z-Score N/A, Piotroski F-Score 1/9).
Investor Implication: At current trailing P/E and current forward P/E within Biotechnology: Pharmaceutical Preparations, upside depends on sustained operating margin expansion (—) and free cash flow conversion relative to the 52-week range of $1.15 – $2.25.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), OSTX is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin —), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).
Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.
Real-time company headlines, analyst actions, and sector developments for OS Therapies Incorporated (OSTX) • Click "Debate This Headline" to argue it in the Roar Pit below
Proceeds from the initial closing, together with accrued refundable U.K. R&D tax credits, expected to provide operating runway through major upcoming milestonesCompany expects to complete early market access regulatory a
Clinical-Stage Oncology Company Taps RPR to Drive Global Communications as Groundbreaking Cancer Immunotherapy Advances Toward ApprovalNEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Rubenstein Public Relations (RPR), a lead
Received notice for upcoming USDA meetingCompany is reviewing strategic alternatives to monetize OS Animal Health ("OSAH")Grasonville, Maryland--(Newsfile Corp. - October 7, 2026) - OS Therapies, Inc. (NYSE American: OST
Leading Clinical Stage Oncology Company Releases Significant Findings from OST-HER2-Treated Patients72.7 percent three-year overall survival vs. 45.8 percent comparable combined historical control (p = 0.0006)Company pre
Experienced biotech leaders to focus on preparations for U.S., U.K., and European commercial launch of the Company's lead product candidate Herlystic™(OST-HER2; daznelimgene lisbac)Grasonville, Maryland--(Newsfile Corp.
New York, New York and Rockville, Maryland--(Newsfile Corp. - September 24, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immun
Recent U.K. MHRA Scientific Advice Meeting (SAM) that resulted in full alignment to initiate confirmatory Phase 3 trial in U.K. with existing Phase 2 drug product paved the way Conditional Marketing Authorisation Applica
FDA aligns with MHRA and EMA on adaptive design for Phase 3 trialAfter successful Scientific Advice Meeting, OS Therapies accepts MHRA request to become the Company's sponsor into Project Orbis to harmonize regulatory re
Welcome to the OSTX (OS Therapies Incorporated) Roar Pit. Current RQD Composite is 42/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on OSTX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless OS Therapies Incorporated expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on OSTX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.24 (52-wk range $1.15 - $2.25), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).